Miriam Michelle Berrey

US Patent:

20130136776, May 30, 2013

Filed:

Nov 27, 2012

Appl. No.:

13/686664

Inventors:

GILEAD PHARMASSET LLC - Foster City CA, US
Charles J. Reynolds - Greenville NC, US
Miriam Michelle Berrey - Durham NC, US
Robert G. Hindes - Skillman NJ, US
William T. Symonds - San Francisco CA, US
Adrian S. Ray - Redwood City CA, US
Hongmei Mo - Palo Alto CA, US
Christy M. Hebner - Belmont CA, US
Reza Oliyai - Burlingame CA, US
Vahid Zia - San Carlos CA, US
Dimitrios Stefanidis - Mountain View CA, US
Rowchanak Pakdaman - San Carlos CA, US
Melissa Jean Casteel - Burlingame CA, US

Assignee:

GILEAD PHARMASSET LLC - Foster City CA

International Classification:

A61K 31/675

US Classification:

424400, 514 86

Abstract:

Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.

US Patent:

20120107278, May 3, 2012

Filed:

Oct 31, 2011

Appl. No.:

13/285444

Inventors:

MIRIAM MICHELLE BERREY - Durham NC, US
William T. Symonds - Cary NC, US

Assignee:

Pharmasset, Inc. - Princeton NJ

International Classification:

A61K 38/21
C12Q 1/70
A61P 31/14

US Classification:

424 857, 435 5

Abstract:

Disclosed herein is a method for administering an abbreviated hepatitis C virus (HCV) treatment regimen for an HCV-infected, rs12979860 single nucleotide polymorphism (SNP) (C/C) patient, which comprises: administering to said patient an effective amount of each of a direct-acting antiviral, pegylated interferon alfa-2a, and ribavirin; wherein the abbreviated HCV treatment regimen is less than 48 weeks. Also disclosed herein is a method of detecting an rs12979860 single nucleotide polymorphism (SNP) in a hepatitis C virus (HCV) infected patient comprising: detecting the rs12979860 SNP of chromosome 19 in a biological sample from a patient, wherein an rs12979860 SNP C/C patient is administered an abbreviated treatment regimen with a direct-acting antiviral agent in combination with peginterferon alfa-2a and ribavirin; and wherein the abbreviated HCV treatment regimen is less than 48 weeks.

US Patent:

20150150896, Jun 4, 2015

Filed:

Nov 11, 2014

Appl. No.:

14/538736

Inventors:

- Foster City CA, US
Charles J. Reynolds - Greenville NC, US
Miriam Michelle Berrey - Durham NC, US
Robert G. Hindes - Skillman NJ, US
William T. Symonds - San Francisco CA, US
Adrian S. Ray - Redwood City CA, US
Hongmei Mo - Palo Alto CA, US
Christy M. Hebner - Belmont CA, US
Reza Oliyai - Burlingame CA, US
Vahid Zia - San Carlos CA, US
Dimitrios Stefanidis - Mountain View CA, US
Rowchanak Pakdaman - San Carlos CA, US
Melissa Jean Casteel - Burlingame CA, US

International Classification:

A61K 31/7072
A61K 31/7056
A61K 9/20

Abstract:

Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.